Loading...

APC anti-mouse CD8a Antibody

Pricing & Availability
Clone
53-6.7 (See other available formats)
Regulatory Status
RUO
Other Names
T8, Lyt2, Ly-2
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
53-6dot7_APC_041106
C57BL/6 mouse splenocytes were stained with CD8 (clone 53-6.7) APC (filled histogram) or rat IgG2a, κ APC isotype control (open histogram).
  • 53-6dot7_APC_041106
    C57BL/6 mouse splenocytes were stained with CD8 (clone 53-6.7) APC (filled histogram) or rat IgG2a, κ APC isotype control (open histogram).
Compare all formats See APC spectral data
Cat # Size Price Quantity Check Availability Save
100711 25 µg 27€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100712 100 µg 84€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD8, also known as Lyt-2, Ly-2, or T8, consists of disulfide-linked α and β chains that form the α(CD8a)/β(CD8b) heterodimer and α/α homodimer. CD8a is a 34 kD protein that belongs to the immunoglobulin family. The CD8 α/β heterodimer is expressed on the surface of most thymocytes and a subset of mature TCR α/β T cells. CD8 expression on mature T cells is non-overlapping with CD4. The CD8 α/α homodimer is expressed on a subset of γ/δ TCR-bearing T cells, NK cells, intestinal intraepithelial lymphocytes, and lymphoid dendritic cells. CD8 is an antigen co-receptor on T cells that interacts with MHC class I on antigen-presenting cells or epithelial cells. CD8 promotes T cell activation through its association with the TCR complex and protein tyrosine kinase lck.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Mouse thymus or spleen
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The CD8a antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 106 cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Red Laser (633 nm)
Application Notes

Clone 53-6.7 antibody competes with clone 5H10-1 antibody for binding to thymocytes3. The 53-6.7 antibody has been reported to block antigen presentation via MHC class I and inhibit T cell responses to IL-2. This antibody has also been used for depletion of CD8a+ cells. Additional reported applications (for the relevant formats) include: immunoprecipitation1,3, in vivo and in vitro cell depletion2,10,15, inhibition of CD8 T cell proliferation3, blocking of cytotoxicity3,4, immunohistochemical staining5,6 of acetone-fixed frozen sections and zinc-fixed paraffin-embedded sections, and spatial biology (IBEX)29,30. Clone 53-6.7 is not recommended for immunohistochemistry of formalin-fixed paraffin sections. The Ultra-LEAF™ purified antibody (Endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays or in vivo studies (Cat No. 100746).

Application References
  1. Ledbetter JA, et al. 1979. Immunol. Rev. 47:63. (IHC, IP)
  2. Hathcock KS. 1991. Current Protocols in Immunology. 3.4.1. (Deplete)
  3. Takahashi K, et al. 1992. P. Natl. Acad. Sci. USA 89:5557. (Block, IP)
  4. Ledbetter JA, et al. 1981. J. Exp. Med. 153:1503. (Block)
  5. Hata H, et al. 2004. J. Clin. Invest. 114:582. (IHC)
  6. Fan WY, et al. 2001. Exp. Biol. Med. 226:1045. (IHC)
  7. Shih FF, et al. 2006. J. Immunol. 176:3438. (FC)
  8. Kamimura D, et al. 2006. J. Immunol. 177:306.
  9. Bouwer HGA, et al. 2006. P. Natl. Acad. Sci. USA 103:5102. (FC, Deplete)
  10. Kao C, et al. 2005. Int. Immunol. 17:1607. PubMed
  11. Ko SY, et al. 2005. J. Immunol. 175:3309. (FC) PubMed
  12. Rasmussen JW, et al. 2006. Infect. Immun. 74:6590. PubMed
  13. Lee CH, et al. 2009. Clin. Cancer Res. PubMed
  14. Geiben-Lynn R, et al. 2008. Blood 112:4585. (Deplete) PubMed
  15. Kingeter LM, et al. 2008. J. Immunol. 181:6244. PubMed
  16. Guo Y, et al. 2008. Blood 112:480. PubMed
  17. Andrews DM, et al. 2008. J. Virol. 82:4931. PubMed
  18. Britschqui MR, et al. 2008. J. Immunol. 181:7681. PubMed
  19. Kenna TJ, et al. 2008. Blood 111:2091. PubMed
  20. Jordan JM, et al. 2008. Infect. Immun. 76:3717. PubMed
  21. Todd DJ, et al. 2009. J. Exp. Med. 206:2151. PubMed
  22. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  23. Medyouf H, et al. 2010. Blood 115:1175. PubMed
  24. Riedl P, et al. 2009. J. Immunol. 183:370. PubMed
  25. Apte SH, et al. 2010. J. Immunol. 185:998. PubMed
  26. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  27. del Rio ML, et al. 2011. Transpl. Int. 24:501. (FC) PubMed
  28. Cui L, et al. 2015. J Control Release. 206:220. PubMed
  29. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  30. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Behr FM, et al. 2021. Eur J Immunol. 51:151. PubMed
  2. Thomas R, et al. 2021. Immunology. 163:478. PubMed
  3. Zhou Y, et al. 2021. Methods Mol Biol. 2388:35. PubMed
  4. Schenkel JM, et al. 2021. Immunity. 54:2338. PubMed
  5. Kragten NAM, et al. 2022. Eur J Immunol. 52:389. PubMed
  6. Li X, et al. 2022. J Clin Invest. 132: . PubMed
  7. Chakraborty P, et al. 2022. Cancer Res. 82:1969. PubMed
  8. Yue Y, et al. 2022. Nat Biomed Eng. 6:898. PubMed
  9. Aghayev T, et al. 2022. Cancer Discov. 12:1960. PubMed
  10. Zhao Z, et al. 2022. Adv Sci (Weinh). 9:e2201293. PubMed
  11. Blanco LP, et al. 2022. Arthritis Rheumatol. 74:1971. PubMed
  12. Marié IJ, et al. 2022. Bio Protoc. 12:e4438. PubMed
  13. Backlund C, et al. 2022. Proc Natl Acad Sci U S A. 119:e2204078119. PubMed
  14. Xie DH, et al. 2022. Med Phys. 49:6728. PubMed
  15. Chen Y, et al. 2023. Adv Healthc Mater. 12:e2202085. PubMed
  16. Theofilatos D, et al. 2022. STAR Protoc. 3:101839. PubMed
  17. Zhu J, et al. 2022. Nat Commun. 13:7466. PubMed
  18. You Q, et al. 2023. Adv Mater. 35:e2204910. PubMed
  19. Yu J, et al. 2022. Nat Commun. 13:7903. PubMed
  20. Morrow RJ, et al. 2022. Cells. 11: . PubMed
  21. Zhao X, et al. 2022. STAR Protoc. 3:101859. PubMed
  22. Ding D, et al. 2023. J Med Chem. 66:1467. PubMed
  23. Lin J, et al. 2023. Nat Commun. 14:224. PubMed
  24. Smith LA, et al. 2023. Front Oncol. 12:1031174. PubMed
  25. Ali LR, et al. 2023. J Exp Med. 220: . PubMed
  26. Kasuya T, et al. 2023. Sci Rep. 13:1653. PubMed
  27. Wang R, et al. 2023. NPJ Vaccines. 8:6. PubMed
  28. Meng S, et al. 2023. Stem Cell Investig. 10:2. PubMed
  29. Zheng J, et al. 2023. Biomater Res. 27:9. PubMed
  30. Zhao M, et al. 2023. J Nanobiotechnology. 21:50. PubMed
  31. Scherer S, et al. 2023. Nat Immunol. 24:501. PubMed
  32. Ye L, et al. 2022. Cell Metab. 34:595. PubMed
  33. Mise Y, et al. 2022. Carcinogenesis. 43:647. PubMed
  34. Stone VM, et al. 2022. iScience. 25:105070. PubMed
  35. Zelenka T, et al. 2022. Nat Commun. 13:6954. PubMed
  36. Choi JG, et al. 2020. Front Immunol. 11:598556. PubMed
  37. Chang YS, et al. 2020. Int J Mol Sci. 21:00. PubMed
  38. Liu Y, et al. 2021. Cell Metabolism. 33(6):1221-1233.e11. PubMed
  39. Glasner A,et al. 2017. Sci Rep.. 10.1038/s41598-017-12998-w. PubMed
  40. Logan K Smith et al. 2018. Immunity. 48(2):299-312 . PubMed
  41. Schuster M, et al. 2017. J Immunol. 199:920. PubMed
  42. Li X et al. 2019. Immunity. 50(3):576-590 . PubMed
  43. O'Malley G, et al. 2018. Cancer Immunol Res. 1.240277778. PubMed
  44. Jiang W, et al. 2017. Sci Rep. 7:6501. PubMed
  45. Xu X, et al. 2020. Chin Med. 15:33. PubMed
  46. Puth S, et al. 2022. Biomaterials. 286:121542. PubMed
  47. Guo A, et al. 2022. Nature. 607:135. PubMed
  48. Chen R, et al. 2022. J Mol Cell Biol. 14:. PubMed
  49. Konjar S, et al. 2022. Proc Natl Acad Sci U S A. 119:e2202144119. PubMed
  50. Cheng C, et al. 2022. Cell Mol Gastroenterol Hepatol. 15:261. PubMed
  51. Pagni RL, et al. 2022. Front Immunol. 13:1005937. PubMed
  52. Chen H, et al. 2023. Nat Commun. 14:941. PubMed
  53. Li X, et al. 2023. J Clin Invest. 133:. PubMed
  54. Kozlovski S, et al. 2023. Front Immunol. 13:1041552. PubMed
  55. Saha S, et al. 2023. Sci Rep. 13:4609. PubMed
  56. Do-Thi VA, et al. 2023. Cancer Res Commun. 3:80. PubMed
  57. Shi Y, et al. 2023. Nat Commun. 14:1884. PubMed
  58. Huang T, et al. 2023. Front Immunol. 14:1124152. PubMed
  59. Wu N, et al. 2023. Front Bioeng Biotechnol. 11:1173381. PubMed
  60. Zhang YT, et al. 2023. Front Immunol. 14:1085456. PubMed
  61. Zhang J, et al. 2023. Theranostics. 13:2226. PubMed
  62. Yu L, et al. 2023. Front Oncol. 13:1174713. PubMed
  63. He Y, et al. 2023. Biomolecules. 13:. PubMed
  64. Deng G, et al. 2023. Cancers (Basel). 15:. PubMed
  65. Wang Y, et al. 2023. iScience. 26:106630. PubMed
  66. Wang K, et al. 2023. Nat Commun. 14:2950. PubMed
  67. Wang D, et al. 2023. Nat Commun. 14:2943. PubMed
  68. Li M, et al. 2023. BMC Cancer. 23:497. PubMed
  69. Zeng S, et al. 2023. Front Oncol. 13:1171926. PubMed
  70. Lan Y, et al. 2023. iScience. 26:106817. PubMed
  71. Zhang AQ, et al. 2023. Nat Biomed Eng. . PubMed
  72. Song S, et al. 2023. Bioact Mater. 28:358. PubMed
  73. Bian L, et al. 2022. Front Immunol. 13:938598. PubMed
  74. Di Martile M, et al. 2020. J Immunother Cancer. 8:. PubMed
  75. Li X, et al. 2022. Nat Commun. 13:2794. PubMed
  76. Zhao X, et al. 2022. Front Mol Biosci. 9:786864. PubMed
  77. Jiang Q, et al. 2022. Theranostics. 12:59. PubMed
  78. Kim D, et al. 2021. Nanomicro Lett. 13:31. PubMed
  79. Renrick AN, et al. 2021. Front Immunol. 607044:12. PubMed
  80. Paris J et al. 2019. Cell Stem Cell. 25(1):137-148 . PubMed
  81. Espinosa-Cueto P, et al. 2017. PLoS One.. 10.1371/journal.pone.0182126. PubMed
  82. Rodriguez-García A, et al. 2021. Nat Commun. 12:877. PubMed
  83. Pan Y, et al. 2021. Front Cell Neurosci. 15:664312. PubMed
  84. Hewitson JP, et al. 2020. J Immunol. 204:2949. PubMed
  85. Xu ZH, et al. 2021. Mediators Inflamm. 2021:8856326. PubMed
  86. Jiang W, et al. 2021. Oncol Lett. 22:625. PubMed
  87. Chen L, et al. 2022. Mol Ther Oncolytics. 24:522. PubMed
  88. Li ZX, et al. 2022. Arch Virol. :. PubMed
  89. Ghosh S, et al. 2022. APL Bioeng. 6:036105. PubMed
  90. Bauer KM, et al. 2022. JCI Insight. 7:. PubMed
  91. Ma Z, et al. 2016. Clin Cancer Res. 22: 2969 - 2980. PubMed
  92. Iwasaki Y, et al. 2016. PLoS One. 11: 0158282. PubMed
  93. Leach SM, et al. 2020. Cell Rep. 33:108337. PubMed
  94. Uzhachenko RV, et al. 2021. Cell Reports. 35(1):108944. PubMed
  95. Christian LS, et al. 2021. Cell Reports. 35(6):109118. PubMed
  96. Dong L, et al. 2021. Cancer Cell. . PubMed
  97. Castiello MC, et al. 2020. J Allergy Clin Immunol. . PubMed
  98. Wang D, et al. 2018. Immunity. 48:659. PubMed
  99. Misumi I et al. 2019. Cell Rep. 27(5):1387-1396 . PubMed
  100. Song C, et al. 2019. Nat Commun. 10:3745. PubMed
  101. Takeda Y, et al. 2018. Innate Immun. 24:323. PubMed
  102. Gupta SS, et al. 2019. Cell Rep. 29:1862. PubMed
  103. Riley JS, et al. 2020. Blood Adv. 4:1102. PubMed
  104. Mayer RL, et al. 2022. Nat Commun. 13:6075. PubMed
  105. Mirshahi F, et al. 2022. Cell Rep. 38:110454. PubMed
  106. del Rio ML, et al. 2021. Transl Res. Online ahead of print.. PubMed
  107. Tian H, et al. 2022. Cancer Sci. 113:875. PubMed
  108. Zhao J, et al. 2022. J Nanobiotechnology. 20:62. PubMed
  109. Fu Y, et al. 2020. Mol Ther. 1214:28. PubMed
  110. Hirano KI, et al. 2021. eLife. 0.416666666666667. PubMed
  111. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
  112. Zheng H, et al. 2021. Frontiers in Cell and Developmental Biology. 9:641527. PubMed
  113. Blumenthal D, et al. 2020. eLife. 9:e55995.. PubMed
  114. Chakrabarti J, et al. 2018. Oncotarget. 9:37439. PubMed
  115. Yuzhu Hou et al. 2018. Immunity. 49(3):490-503 . PubMed
  116. Oyarce C, et al. 2018. Front Immunol. 8:1794. PubMed
  117. Bommireddy R, et al. 2020. Vaccines (Basel). 8:. PubMed
  118. Yin Y, et al. 2021. ACS Nano. 15:14347. PubMed
  119. Xu F, et al. 2022. Cell Death Discov. 8:142. PubMed
  120. Felker A, Croy B 2016. J Leukoc Biol. 100: 645 - 655. PubMed
  121. Wagner V, et al. 2016. Sci Transl Med. 8: 366ra164. PubMed
  122. He C, et al. 2020. Clin Transl Med. 10:e39. PubMed
  123. Pan H, et al. 2020. Mol Psychiatry. . PubMed
  124. Chen S et al. 2018. Cell reports. 25(7):1729-1740 . PubMed
  125. Hayatsu N et al. 2017. Immunity. 47(2):268-283 . PubMed
  126. Misumi I et al. 2019. Cell Rep. 27(2):514-524 . PubMed
  127. Zhang F, et al. 2019. Nat Commun. 10:3974. PubMed
  128. Lee JH, et al. 2018. Transgenic Res. 27:241. PubMed
  129. Demircioglu F, et al. 2020. Nat Commun. 11:1290. PubMed
  130. Guo H, et al. 2022. PLoS Pathog. 18:e1010857. PubMed
  131. Frey N, et al. 2022. Nat Commun. 13:1804. PubMed
  132. Zhang J, et al. 2022. Front Immunol. 13:931740. PubMed
  133. Bhattacharya P, et al. 2022. PLoS Negl Trop Dis. 16:e0010224. PubMed
  134. Zhan Y, et al. 2021. JCI Insight. 6:. PubMed
  135. Zhan CS, et al. 2020. FASEB J. 14006:34. PubMed
  136. Mitchell JE, et al. 2021. Cell Reports. 35(2):108966. PubMed
  137. Han C, et al. 2021. Cell Reports. 34(6):108706. PubMed
  138. Lebratti T, et al. 2021. eLife. 10:00. PubMed
  139. Eriksson E, et al. 2016. Gene Ther. 10.1038/gt.2016.80. PubMed
  140. Shade K, et al. 2015. J Exp Med. 212:457. PubMed
  141. Zhang C, et al. 2020. Cell Metabolism. 31(1):148-161.e5.. PubMed
  142. Lu Y, et al. 2020. Cell. 180(6):1081-1097. PubMed
  143. Uchimura T et al. 2018. Immunity. 49(6):1049-1061 . PubMed
  144. Li Y, et al. 2019. Oncol Rep. 41:2679. PubMed
  145. Tran L, et al. 2017. Cancer Immunol Res. 5:1141. PubMed
  146. Wang L, et al. 2021. Cancer Immunol Res. 9:348. PubMed
  147. Si L, et al. 2022. Nat Biotechnol. 40:1370. PubMed
  148. Ebina-Shibuya R, et al. 2021. Elife. 10:. PubMed
  149. Yin Q, et al. 2015. PLoS One. 10: 0137808. PubMed
  150. Vieyra-Garcia P, et al. 2016. Clin Cancer Res. 22: 3328 - 3339. PubMed
  151. Matsumura K, et al. 2016. J Immunol. 197: 3233 - 3244. PubMed
  152. Paiva RA, et al. 2021. Cell Reports. 35(2):108967. PubMed
  153. Solanki A, et al. 2018. Development. 145. PubMed
  154. Koliaraki V et al. 2019. Cell reports. 26(3):536-545 . PubMed
  155. Zhang F, et al. 2019. Immunity. 50:738. PubMed
  156. Riffelmacher T et al. 2017. Immunity. 47(3):466-480 . PubMed
  157. Caronni N, et al. 2018. Cancer Res. 78:1685. PubMed
  158. He X, et al. 2021. Small. 17:e2007165. PubMed
  159. Pervaiz N, et al. 2021. Pigment Cell Melanoma Res. 34:918. PubMed
  160. Katsinas N, et al. 2022. J Clin Med. 11:. PubMed
  161. He X, et al. 2021. Adv Sci (Weinh). 8:e2103023. PubMed
  162. Jeong SH, et al. 2021. Nat Commun. 12:4405. PubMed
  163. Huang Y, et al. 2020. FASEB J. 34:1768. PubMed
  164. Aegerter H, et al. 2020. Nat Immunol. 0.975694444. PubMed
  165. Poczobutt J, et al. 2016. J Immunol. 196: 891 - 901. PubMed
  166. Brummer G, et al. 2020. Oncogene. 39:2275. PubMed
  167. Maluski M, et al. 2019. J Clin Invest. 129:5108. PubMed
  168. Soldevilla MM, et al. 2019. Mol Ther. 27:1878. PubMed
  169. Liu D et al. 2019. Immunity. 51(1):64-76 . PubMed
  170. Luo Y et al. 2019. Cell reports. 26(7):1869-1879 . PubMed
  171. Miska J et al. 2019. Cell reports. 27(1):226-237 . PubMed
  172. Liu J, et al. 2019. J Exp Med. 216:656. PubMed
  173. Funk KE, et al. 2019. J Neuroinflammation. 16:22. PubMed
  174. Cong J et al. 2018. Cell metabolism. 28(2):243-255 . PubMed
  175. Divan A, et al. 2018. PLoS One. 13:e0196893. PubMed
  176. Alikhanyan K, et al. 2021. Cancers (Basel). 13:. PubMed
  177. Chen Q, et al. 2016. Nat Commun. 7:13193. PubMed
  178. Hoefflin R, et al. 2020. Nat Commun. 3.313194444. PubMed
  179. Espinosa JR, et al. 2018. Front Immunol. 9:1371. PubMed
  180. Lee JS et al. 2018. Cell. 174(6):1559-1570 . PubMed
  181. Schadt L, et al. 2020. Cell Reports. 29(5):1236-1248.e7.. PubMed
  182. Zheng Z, et al. 2020. Cell Death Dis. 0.684722222. PubMed
  183. Xu H, et al. 2020. Immunity. 51(4):696-708.e9.. PubMed
  184. Zhao X, et al. 2022. Nat Protoc. 17:2240. PubMed
  185. He X, et al. 2022. Cancer Immunol Res. 10:314. PubMed
  186. Liu T, et al. 2022. Front Immunol. 13:901349. PubMed
  187. Zhang C, et al. 2022. Nat Commun. 13:3468. PubMed
  188. Goldfarb Y, et al. 2021. J Exp Med. 218:. PubMed
  189. Ye P, et al. 2022. Front Cardiovasc Med. 8:810477. PubMed
  190. Chen G, et al. 2021. Sci Adv. 7:eabg5686. PubMed
  191. Tartey S, et al. 2021. Cancer Research. 81(9):2358-2372. PubMed
  192. Elahi S, et al. 2020. Stem Cell Res. 43:101710. PubMed
  193. Bayik D, et al. 2020. Cancer Discov. 1.256944444. PubMed
  194. Yi X, et al. 2020. Sci Adv. 6:eaba3546. PubMed
  195. Vidy A, et al. 2016. PLoS One. 11:e0165361. PubMed
  196. Mirando AC, et al. 2020. Oncoimmunology. 9:1760685. PubMed
  197. Horiguchi H, et al. 2019. Genes Dev. 33:1641. PubMed
  198. Bai C, et al. 2020. Mol Ther Oncolytics. 17:9. PubMed
  199. Leal AS, et al. 2019. Sci Rep. 5.286111111. PubMed
  200. Al–Zaher AA, et al. 2018. Mol Ther Oncolytics. 0.376388889. PubMed
  201. Li W, et al. 2019. Nat Commun. 10:3349. PubMed
  202. Budida R, et al. 2017. Eur J Immunol. 47:1819. PubMed
  203. Reismann D, et al. 2017. Nat Commun.. 10.1038/s41467-017-01538-9. PubMed
  204. Ishidome T et al. 2017. EBioMedicine. 22:89-99 . PubMed
  205. Oka Y, et al. 2020. Sci Adv. 6:. PubMed
  206. Haas MS, et al. 2020. Mol Cancer Res. 19:717. PubMed
  207. Jiang Y, et al. 2020. Adv Mater. 32:e2001808. PubMed
  208. Shannon JP, et al. 2021. STAR Protoc. 2:100790. PubMed
  209. Li H, et al. 2021. Nat Commun. 12:7149. PubMed
  210. Dey S, et al. 2020. J Immunother Cancer. 8:. PubMed
  211. Wu H, et al. 2021. Cell Death Discov. 7:225. PubMed
  212. Shen M, et al. 2022. Nat Cancer. 3:60. PubMed
  213. Zhang Q, et al. 2022. Nat Commun. 13:2406. PubMed
  214. Germundson DL, et al. 2022. Front Allergy. 3:870513. PubMed
  215. Li YN, et al. 2022. Nat Commun. 13:4074. PubMed
  216. Gibbins J, et al. 2014. Blood. 124:2953. PubMed
  217. Ku C, et al. 2015. Genes Dev. 29: 1930-1941. PubMed
  218. Cook KD, et al. 2015. Immunity. 43:703-714. PubMed
  219. Latasa C, et al. 2016. PLoS One. 11: 0161216. PubMed
  220. Holokai L, et al. 2020. Cancers (Basel). 12:00. PubMed
  221. Wanner-Seleznik GM, et al. 2020. Immunohorizons. 0.644444444. PubMed
  222. Zeng W, et al. 2021. STAR Protocols. 2(1):100361. PubMed
  223. Vaena S, et al. 2021. Cell Reports. 35(5):109076. PubMed
  224. Ren W, et al. 2018. Mucosal Immunol. 12:531. PubMed
  225. Hu J, et al. 2019. Mol Ther Nucleic Acids. 16:650. PubMed
  226. Matsuo K, et al. 2018. J Immunol. 200:800. PubMed
  227. Takaku S, et al. 2020. Integr Cancer Ther. 19:1534735419900798. PubMed
  228. Alikhanyan K, et al. 2020. Immun Inflamm Dis. 8:181. PubMed
  229. Medyouf H, et al. 2010. Blood. 115:1175. PubMed
  230. Yang Z, et al. 2021. Onco Targets Ther. 14:4239. PubMed
  231. Otvos B, et al. 2021. Clin Cancer Res. 27:2038. PubMed
  232. Ding P, et al. 2022. Bone Res. 10:42. PubMed
  233. Li Y, et al. 2021. Cell Death Dis. 12:1001. PubMed
  234. Bates PD, et al. 2021. Front Immunol. 12:668307. PubMed
  235. Shannon JP, et al. 2021. Immunity. 54(2):276-290.e5. PubMed
  236. Oguri Y, et al. 2020. Cell. 182(3):563-577.e20. PubMed
  237. Guo H, et al. 2014. J Leukoc Biol. 96:419. PubMed
  238. Lin W, et al. 2019. EBioMedicine. 49:133. PubMed
  239. Chen Z, et al. 2019. J Exp Med. 216:152. PubMed
  240. Nam GH, et al. 2018. Nat Commun. 9:2165. PubMed
  241. Chatterjee S et al. 2017. Cell metabolism. 27(1):85-100 . PubMed
  242. Hu Y, et al. 2021. Cell Death Dis. 12:743. PubMed
  243. Schreiber K, et al. 2020. Cancer Immunol Res. 8:192. PubMed
  244. Feng Y, et al. 2022. J Nanobiotechnology. 20:193. PubMed
  245. Sun S, et al. 2013. J Immunol. 190:6209. PubMed
  246. Wang H, et al. 2020. Nat Mater. 1.655555556. PubMed
  247. Nanou A, et al. 2021. Cell Reports. 35(8):109168. PubMed
  248. Lin YH, et al. 2018. Cancer Immunol Res. 0.25. PubMed
  249. Morelli AE, et al. 2020. Cell Rep. 30:3448. PubMed
  250. Zhang NN, et al. 2020. Cell. 182(5):1271-1283. PubMed
  251. Mohamed E, et al. 2020. Immunity. 52(4):668-682.e7.. PubMed
  252. Wang Y, et al. 2021. Nat Commun. 12:4964. PubMed
  253. Takahashi F, et al. 2022. iScience. 25:104278. PubMed
  254. Qi J, et al. 2021. Nat Commun. 12:4755. PubMed
  255. Robertson TF, et al. 2021. J Cell Biol. 220:. PubMed
  256. Nasarre P, et al. 2021. Cancers (Basel). 13: . PubMed
  257. Li X, et al. 2021. Cell Death Dis. 12:314. PubMed
  258. Chen R, et al. 2021. Cell Reports. 34(7):108751. PubMed
  259. Alexandre YO, et al. 2020. Cell Reports. 33(13):108567. PubMed
  260. Nahrendorf W, et al. 2021. eLife. 10:00. PubMed
  261. Gong N, et al. 2020. Nat Nanotechnol. 1.35625. PubMed
  262. Wu L, et al. 2020. Cell Rep. 33:108327. PubMed
  263. Swanson P, et al. 2016. PLoS Pathog. 12:e1006022. PubMed
  264. Teo T, et al. 2015. J Virol. 89: 7955-7969. PubMed
  265. Sasaki Y, et al. 2015. PLoS One. 10: 0131176. PubMed
  266. Spangenberg E, et al. 2019. Nat Commun. 10:3758. PubMed
  267. Frazer GL, et al. 2021. J Cell Biol. 220:. PubMed
  268. Do-Thi VA, et al. 2021. Cancers (Basel). 13:. PubMed
  269. Wang J, et al. 2022. Clin Transl Med. 12:e718. PubMed
  270. Kataru RP, et al. 2022. Front Aging. 3:864860. PubMed
  271. Zhao X, et al. 2022. iScience. 25:104690. PubMed
  272. Huber MK, et al. 2021. J Vis Exp. :. PubMed
  273. Chen H, et al. 2022. Front Pharmacol. 13:827520. PubMed
  274. Ma Q, et al. 2022. Vaccines (Basel). 10:. PubMed
  275. Fonderflick L, et al. 2022. Cells. 11:. PubMed
  276. Rao L, et al. 2020. Nat Commun. 11:4909. PubMed
  277. Murata T, et al. 2020. Sci Rep. 10:13560. PubMed
  278. He X, et al. 2021. J Immunother Cancer. 9:. PubMed
  279. Zheng Z, et al. 2021. Nat Commun. 12:6202. PubMed
  280. Kiss M, et al. 2020. Cancer Immunol Res. 9:309. PubMed
  281. Dallari S, et al. 2021. Cell Host Microbe. 29(6):1014-1029.e8. PubMed
  282. Ulaganathan VK, et al. 2020. Sci Rep. 10:8453. PubMed
  283. Li X, et al. 2017. Front Immunol. 8:1186. PubMed
  284. Schuster M, et al. 2019. Front Immunol. 10:1583. PubMed
  285. Fang W, et al. 2021. J Exp Clin Cancer Res. 40:4. PubMed
  286. Zheng Z, et al. 2021. Biomed Res Int. 2021:5535578. PubMed
  287. Jiang Y, et al. 2021. Nat Commun. 12:742. PubMed
  288. Zhang Z, et al. 2020. Nature. 579:415. PubMed
  289. Harrison DK, et al. 2021. Transplantation. 105:540. PubMed
  290. Tassi I, et al. 2014. J Immunol. 193:4303. PubMed
  291. Kramer K, et al. 2017. Mol Ther. 25(1):62-70. PubMed
  292. Zheng DW, et al. 2020. Nat Commun. 3.865972222. PubMed
  293. Yin X, et al. 2020. Cell Rep. 33:108278. PubMed
  294. Lu C, et al. 2020. Cancer Cell. 39(1):96-108.e6. PubMed
  295. Gaya M et al. 2018. Cell. 172(3):517-533 . PubMed
  296. Zhang J, et al. 2018. Oncoimmunology. 7:e1461301. PubMed
  297. Yoshida H, et al. 2019. Cell. 176:897. PubMed
  298. Chao Y, et al. 2020. Sci Adv. 6:eaaz4204. PubMed
  299. Kataru RP, et al. 2019. Cancer Immunol Res. 7:1345. PubMed
  300. Liu YW, et al. 2022. JCI Insight. 7:. PubMed
  301. Sun Y, et al. 2022. iScience. 25:104846. PubMed
  302. Chen B, et al. 2021. Cell. 184:6262. PubMed
  303. Smith LK, et al. 2021. Elife. 10:. PubMed
  304. Nagatake T, et al. 2021. Int Immunol. 33:171. PubMed
  305. Tang-Huau TL, et al. 2021. Viruses. 13: . PubMed
  306. Ukidve A, et al. 2020. Proc Natl Acad Sci U S A. 117:17727. PubMed
  307. Pelly V, et al. 2016. Mucosal Immunol. 10.1038/mi.2016.4. PubMed
  308. Chen S, et al. 2015. Cancer Res . 7: 519-531. PubMed
  309. Chakraborty P, et al. 2020. Cell Reports. 28(7):1879-1893.e7.. PubMed
  310. Han P, et al. 2020. Sci Adv. 6:eaaz1580. PubMed
  311. Nakamura K, et al. 2018. Cancer Cell. 33:634. PubMed
  312. Tippimanchai DD, et al. 2018. Oncoimmunology. 7:e1438105. PubMed
  313. Cong L, et al. 2021. Breast Cancer Res. 23:51. PubMed
  314. Dourcy M, et al. 2020. Mucosal Immunol. 13:799. PubMed
  315. Zhou P, et al. 2022. Mol Ther Oncolytics. 25:236. PubMed
  316. Zheng Y, et al. 2022. Transl Res. :. PubMed
  317. Funk KE, et al. 2021. Aging Cell. 20:e13412. PubMed
  318. Tian T, et al. 2020. Cancer Immunol Res. 660:8. PubMed
  319. Konishi Y, et al. 2018. iScience. 10:98. PubMed
  320. Wang J, et al. 2020. J Hematol Oncol. 0.610416667. PubMed
  321. Zhang Y, et al. 2022. J Immunother Cancer. 10:. PubMed
  322. Bessell CA, et al. 2020. JCI Insight. 5:. PubMed
  323. Li C, et al. 2022. Front Cell Dev Biol. 10:913824. PubMed
  324. Tseng SH, et al. 2021. J Biomed Sci. 28:63. PubMed
  325. Li X, et al. 2021. Front Immunol. 12:779560. PubMed
  326. Galeano Nio JL, et al. 2020. eLife. 9:00. PubMed
  327. Liu WL, et al. 2019. Nat Commun. 10:3199. PubMed
  328. Johnson JL et al. 2018. Immunity. 48(2):243-257 . PubMed
RRID
AB_312750 (BioLegend Cat. No. 100711)
AB_312750 (BioLegend Cat. No. 100712)

Antigen Details

Structure
Ig superfamily, CD8α chain, 34 kD
Distribution

Most thymocytes, T cell subset, some NK cells, lymphoid dendritic cells

Function
Co-receptor for TCR
Ligand/Receptor
MHC class I molecule
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Zamoyska R. 1994. Immunity 1:243.
3. Ellmeier W, et al. 1999. Annu. Rev. Immunol. 17:523.

Gene ID
12525 View all products for this Gene ID
UniProt
View information about CD8alpha on UniProt.org

Related FAQs

There are no FAQs for this product.

Other Formats

View All CD8a Reagents Request Custom Conjugation
Description Clone Applications
APC anti-mouse CD8a 53-6.7 FC
Biotin anti-mouse CD8a 53-6.7 FC,IHC
FITC anti-mouse CD8a 53-6.7 FC
PE anti-mouse CD8a 53-6.7 FC
PE/Cyanine5 anti-mouse CD8a 53-6.7 FC
Purified anti-mouse CD8a 53-6.7 FC,CyTOF®,IHC-F,IP
PE/Cyanine7 anti-mouse CD8a 53-6.7 FC
APC/Cyanine7 anti-mouse CD8a 53-6.7 FC
Alexa Fluor® 488 anti-mouse CD8a 53-6.7 FC,3D IHC
Alexa Fluor® 647 anti-mouse CD8a 53-6.7 FC,IHC-F,3D IHC,SB
Pacific Blue™ anti-mouse CD8a 53-6.7 FC
Alexa Fluor® 700 anti-mouse CD8a 53-6.7 FC
PerCP/Cyanine5.5 anti-mouse CD8a 53-6.7 FC
PerCP anti-mouse CD8a 53-6.7 FC
Brilliant Violet 421™ anti-mouse CD8a 53-6.7 FC,IHC,SB
Brilliant Violet 570™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 650™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 605™ anti-mouse CD8a 53-6.7 FC
Ultra-LEAF™ Purified anti-mouse CD8a 53-6.7 FC,CyTOF®,IHC,IP,Depletion,Block
Brilliant Violet 711™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 785™ anti-mouse CD8a 53-6.7 FC
Brilliant Violet 510™ anti-mouse CD8a 53-6.7 FC
Purified anti-mouse CD8a (Maxpar® Ready) 53-6.7 FC,CyTOF®
Alexa Fluor® 594 anti-mouse CD8a 53-6.7 IHC-F,FC,3D IHC
PE/Dazzle™ 594 anti-mouse CD8a 53-6.7 FC
APC/Fire™ 750 anti-mouse CD8a 53-6.7 FC
GoInVivo™ Purified anti-mouse CD8a 53-6.7 FC
TotalSeq™-A0002 anti-mouse CD8a 53-6.7 PG
Spark Blue™ 550 anti-mouse CD8a 53-6.7 FC
Spark NIR™ 685 anti-mouse CD8a 53-6.7 FC
TotalSeq™-C0002 anti-mouse CD8a 53-6.7 PG
TotalSeq™-B0002 anti-mouse CD8a 53-6.7 PG
Spark YG™ 570 anti-mouse CD8a 53-6.7 IHC-F
PE/Fire™ 640 anti-mouse CD8a 53-6.7 FC
PE/Fire™ 700 anti-mouse CD8a 53-6.7 FC
Spark Blue™ 574 anti-mouse CD8a Antibody 53-6.7 FC
Spark Violet™ 423 anti-mouse CD8a Antibody 53-6.7 FC
Spark UV™ 387 anti-mouse CD8a 53-6.7 FC
Spark Blue™ 515 anti-mouse CD8a 53-6.7 FC
APC/Fire™ 810 anti-mouse CD8a 53-6.7 FC
Spark Red™ 718 anti-mouse CD8a (Flexi-Fluor™) 53-6.7 FC
PE/Fire™ 810 anti-mouse CD8a 53-6.7 FC
Spark PLUS UV395™ anti-mouse CD8a 53-6.7 FC
PerCP/Fire™ 780 anti-mouse CD8a 53-6.7 FC
Go To Top Version: 2    Revision Date: 01-21-2014

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account